Dr. Reddy's Laboratories Launches Palonosetron Hydrochloride Injection in US Market
27 March 2018 - - Hyderabad, India-based integrated pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE: 500124) NSE: DRREDDY) (NYSE: RDY) has launched Palonosetron Hydrochloride Injection, 0.25 mg / 5 mL, a therapeutic equivalent generic version of Aloxi (palonosetron hydrochloride) Injection approved by the US Food and Drug Administration (USFDA), the company said.
The Aloxi brand and generic had US sales of approximately USD446 m MAT for the most recent twelve months ending in January 2018 according to IMS Health*.
Dr. Reddy's Palonosetron Hydrochloride Injection is available in a strength of 0.25 mg/5 mL (free base) in a single-dose vial packaged in a carton containing one vial.
Dr. Reddy's is committed to providing affordable and innovative medicines through its three businesses - pharmaceutical services and active ingredients, global generics, and proprietary products.
The company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, and differentiated formulations. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
Dr. Reddy's operates in markets across the globe, including the US, India, Russia and CIS countries, and Europe.